Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Gynecologic 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Vulvar Neoplasms 1Uterine Cervical Neoplasms 1Rectal Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Melanoma 1Head and Neck Neoplasms 1Endometrial Neoplasms 1Carcinoma, Squamous Cell 1Breast Neoplasms 1Anus Neoplasms 1

Interventions

pembrolizumab 21Cyclophosphamide 18fludarabine 8Radiotherapy 8Radiosurgery 7Nivolumab 7poly ICLC 6fludarabine phosphate 6aldesleukin 6Therapeutics 6Paclitaxel 6Magnetic Resonance Spectroscopy 6durvalumab 5Psychiatric Rehabilitation 5Interleukin-2 5Drug Therapy 5Docetaxel 5Cisplatin 5temsirolimus 4cemiplimab 4Trastuzumab 4Temozolomide 4Sirolimus 4Gemcitabine 4Flow Cytometry 4Filgrastim 4Carboplatin 4tremelimumab 3technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran 3pazopanib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Breast Neoplasms × nanocis × Dermatologic × Clear all
NCT02997553 2023-01-09

GASVERT

Institut de Cancérologie de Lorraine

Phase 3 Completed
744 enrolled
BreastDermatologicGastrointestinalGynecologicHead & Neck

Anus Neoplasms, Breast Neoplasms, Carcinoma, Squamous Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Melanoma, Neoplasms, Ovarian Neoplasms, Rectal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡